Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00390208 · ClinicalTrials.gov registry record · Phase 2
Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration
A Phase 2 study of Age-related Macular Degeneration, sponsored by Bay Area Retina Associates.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 4
- Study locations
NCT00390208: Completed Phase 2 study of Age-related Macular Degeneration, sponsored by Bay Area Retina Associates.
NCT00390208 is a Phase 2 study of Age-related Macular Degeneration that has completed, run by Bay Area Retina Associates. The registered enrollment target is 60 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00390208, a Phase 2 study of Age-related Macular Degeneration, has completed, sponsored by Bay Area Retina Associates.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to compare triple therapy using Photodynamic therapy, intravitreal Dexamethasone and intravitreal Ranibizumab injections versus monotherapy with intravitreal Ranibizumab alone for the treatment of Age-Related Macular Degeneration.
Conditions Studied
Interventions
- DRUG Ranibizumab
- DRUG ranibizumab, dexamethasone and verteporfin
Study Locations (4)
California
- Bay Area Retina Associates - Castro Valley
- Bay Area Retina Associates - Walnut Creek
Georgia
- Georgia Retina - Riverdale
Ohio
- Retina Vitreous Associates - Toledo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2006-08 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
What the finished NCT00390208 record still lists
NCT00390208 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Ranibizumab is the first listed.
NCT00390208 reports a single indexed study location in California, Georgia, Ohio.
Frequently Asked Questions
What is clinical trial NCT00390208 about?
NCT00390208 is a clinical study titled "Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration". The purpose of this study is to compare triple therapy using Photodynamic therapy, intravitreal Dexamethasone and intravitreal Ranibizumab injections versus monotherapy with intravitreal Ranibizumab alone for the treatment of Age-Related Macular Degeneration.
What is the current status of trial NCT00390208?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2006-08. Estimated completion is 2009-12.
What conditions does trial NCT00390208 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration.
What interventions are being tested in trial NCT00390208?
The interventions under investigation include: Ranibizumab (DRUG), ranibizumab, dexamethasone and verteporfin (DRUG).
Who is sponsoring clinical trial NCT00390208?
This trial is sponsored by Bay Area Retina Associates, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00390208 being conducted?
This trial has 4 study locations across California, Georgia, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00390208's enrollment target sits among peer trials
60 42nd of 74 higher than 31 of 74 other Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD
RECRUITING · Phase 2
-
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 2
-
Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
COMPLETED · Phase 2
-
A Study to Evaluate the Safety and Efficacy of RQC for AMD
COMPLETED · Phase 2
-
ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA
COMPLETED · Phase 2
-
Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia